Free Trial
OTCMKTS:CYBN

Cybin (CYBN) Stock Price, News & Analysis

Cybin logo
$10.12
+0.13 (+1.30%)
(As of 11/4/2024 ET)

About Cybin Stock (OTCMKTS:CYBN)

Key Stats

Today's Range
$9.85
$10.15
50-Day Range
$0.20
$11.42
52-Week Range
$6.50
$22.31
Volume
60,323 shs
Average Volume
142,638 shs
Market Capitalization
$202.32 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Buy

Company Overview

Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation. It has also developed EMBARK, a psychological support model that integrates clinical approaches to promote supportive healing with psychedelic medicine. The company is headquartered in Toronto, Canada.

Receive CYBN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cybin and its competitors with MarketBeat's FREE daily newsletter.

CYBN Stock News Headlines

625,000% Gain
Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.
Cybin Inc (R7E1.DU)
See More Headlines

CYBN Stock Analysis - Frequently Asked Questions

Cybin's stock was trading at $0.41 at the start of the year. Since then, CYBN shares have increased by 2,368.3% and is now trading at $10.12.
View the best growth stocks for 2024 here
.

Cybin Inc. (OTCMKTS:CYBN) released its earnings results on Thursday, August, 8th. The company reported ($0.01) earnings per share for the quarter.

Shares of CYBN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cybin investors own include NVIDIA (NVDA), Meta Platforms (META), Pfizer (PFE), Advanced Micro Devices (AMD), Broadcom (AVGO), CrowdStrike (CRWD) and Palantir Technologies (PLTR).

Company Calendar

Last Earnings
8/08/2024
Today
11/04/2024
Fiscal Year End
3/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
Pharmaceutical Products
Current Symbol
OTCMKTS:CYBN
Fax
N/A
Employees
50
Year Founded
N/A

Profitability

Net Income
$-35,930,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$680,000.00
Book Value
$0.19 per share

Miscellaneous

Free Float
170,213,000
Market Cap
$202.32 million
Optionable
Not Optionable
Beta
0.38
(Almost)  Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

This page (OTCMKTS:CYBN) was last updated on 11/5/2024 by MarketBeat.com Staff
From Our Partners